Skip to main content
logo
Goldline Pharmaceutical Limited (BOM:544759)
India flag India · Delayed Price · Currency is INR
39.25
-1.95 (-4.73%)
At close: Aug 4, 2026

Goldline Pharmaceutical Financials Overview

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
311.99311.99280.56235.66198.48240.11
Revenue Growth
29.94%11.20%19.05%18.73%-17.34%9.66%
Gross Profit
200.09200.09172.16174.8139.9986.08
Operating Income
676758.9741.8222.3916.54
Net Income
41.1741.1728.3418.062.573.32
Earnings Per Share
5.975.974.113.010.430.55
EPS Growth
978.98%45.34%36.52%603.53%-22.71%61.17%

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
5.925.9212.47.90.541.41
Total Debt
91.6291.62110.34111.3108.29103.13
Net Cash (Debt)
-85.69-85.69-97.95-103.4-107.75-101.72
Net Cash Growth
------
Net Cash Per Share
-12.43-12.43-14.20-17.23-17.96-16.97

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
28.1528.1523.2129.2223.91-
Capital Expenditures
-0.57-0.57-2.07-11.09-11.08-
Free Cash Flow
27.5827.5821.1418.1412.83-
Free Cash Flow Growth
-30.44%16.58%41.36%--

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
64.13%64.13%61.37%74.17%70.53%35.85%
Operating Margin
21.48%21.48%21.02%17.75%11.28%6.89%
Pretax Margin
17.26%17.26%13.75%10.72%2.02%1.88%
Profit Margin
13.20%13.20%10.10%7.66%1.29%1.38%
FCF Margin
8.84%8.84%7.54%7.70%6.46%-